Deliver Your News to the World

BioCurex Poised For Positive Future Based On Results (OTC:BOCX)


MiV Investments Inc. initiates independent research on BioCurex, Inc. (OTC:BOCX). It is a biotechnology company developing products for cancer diagnosis, imaging, and therapy that target a global oncology market forecast to reach over $50 billion by 2009.

The Company uses a novel, patented technology based on the RECAF™ cancer marker, discovered by Dr. Ricardo Moro-Vidal, BioCurex’s chief executive officer (CEO), president, and founder. RECAF™ is a molecule found on malignant† cells but absent from most normal or benign cells. BioCurex believes that the detection of this molecule in tissue or serum samples is the foundation for new cancer diagnostic tests and imaging techniques.

The RECAF™ marker has been found on every cancer tissue that BioCurex has studied to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This characteristic indicates that RECAF™ is capable of detecting more than one type of cancer, which is a limitation of many currently available cancer markers.

The Company’s RECAF™ technology is reported to have high levels of clinical sensitivity and specificity (measures of cancer marker accuracy), successfully detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF™ recently identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostate specific antigen (PSA) test. A RECAF™-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives.

This data supports BioCurex’s aim of reducing human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to its ability to differentiate between cancerous and normal cells, RECAF™ technology may facilitate the administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.

The current state of cancer detection

• According to the World Health Organization the number of people diagnosed with malignant tumors will increase by 50% in a dozen years.

• Survival rates depend mostly on how early the disease is discovered. i.e. The five-year survival rate for breast
cancer ranges from 87% at Stage I to only 13% at Stage IV.) RECAF technology detects malignancy earlier, more accurately, and potentially far more cost-effectively.

• Current cancer detection is still primitive. Needle and surgical biopsies are the most accurate, but far from
perfect. They’re also highly intrusive and can cause serious infections. Blood testing, as it now exists, is much less accurate and rife with false positives. (i.e. PSA is a mediocre marker for prostate cancer. It catches only 80% of malignancies — yet produces 65% false positives in patients with benign tumors that usually require no treatment. Yet, all too often, patients are still subjected to costly and debilitating surgical procedures.)

The full special report on the company appears today at ..

Disclosure: Long BOCX

To feature a publicly traded company in Alerts or as a fully profiled company, email us at or visit for more info


About MiV Investments Inc.

MiV Investments Inc. can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 otc bocx
 recaf lung cancer

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.